[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

2019 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

April 2019 | 118 pages | ID: 239D0EDA029EN
VPAResearch

US$ 1,799.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The global clinical trial report- “2019 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections. It presents in-depth analysis of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections clinical trials across markets and companies. The research work is for providing complete understanding into trends in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections clinical trials by-
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

The research work is prepared through extensive and continuous research on Methicillin-Resistant Staphylococcus aureus (MRSA) Infections trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Methicillin-Resistant Staphylococcus aureus (MRSA) Infections patients are identified
  • The report includes panorama of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Methicillin-Resistant Staphylococcus aureus (MRSA) Infections clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
1. TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2. EXECUTIVE SUMMARY

2.1 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
  2.2.1 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials by Region
  2.2.2 Average Enrollment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials
  2.2.3 Companies participating in Trials
  2.2.4 Drugs under Study for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Treatment, 2019

3. REGION WISE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) INFECTIONS CLINICAL TRIALS

3.1 Asia Pacific Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials by Country
3.2 Europe Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials by Country
3.3 North America Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials by Country
3.4 Middle East and Africa Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials by Country
3.5 South and Central America Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials by Country

4. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) INFECTIONS CLINICAL TRIAL TRENDS

4.1 Start Year wise Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials
4.2 Phase wise Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials
4.3 Trial Status wise Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials
4.4 Trial Type wise Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials

5. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) INFECTIONS AVERAGE ENROLLMENT TRENDS

5.1 Average Enrollment in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Trials by Year
5.2 Average Enrollment in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Trials by Phase
5.3 Average Enrollment in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Trials by Status
5.4 Average Enrollment in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Trials by Type of Trial

6. COMPANIES PARTICIPATING IN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) INFECTIONS CLINICAL TRIALS

6.1 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Trials by Sponsor Type
6.2 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS

7.1 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Trials- Phase
7.2 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Trials- Phase
7.3 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Trials- Phase
7.4 Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Trials- Phase

8. APPENDIX

8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

LIST OF FIGURES

Figure 1: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials and Enrolment
Figure 5: Europe – Country wise Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials and Enrolment
Figure 7: North America – Country wise Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials and Enrolment
Figure 9: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials by Phase
Figure 10: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials by Trial Status
Figure 11: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials by Type
Figure 12: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials by Sponsor Type
Figure 13: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials by Leading Sponsors
Figure 14: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Average Enrollment by Phase
Figure 15: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Average Enrollment by Trial Status
Figure 16: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Average Enrollment by Type
Figure 17: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections- Average Enrolment by Type of Sponsors
Figure 18: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

LIST OF TABLES

Table 1: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials and Enrolment
Table 5: Europe – Country wise Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials and Enrolment
Table 7: North America – Country wise Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Average Enrollment by Phase
Table 15: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Average Enrollment by Trial Status
Table 16: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Average Enrollment by Type
Table 17: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections- Average Enrolment by Type of Sponsors
Table 18: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections- Enrolment by Leading Sponsors

More Publications

Need Help?

Ask a Question

Market Reports

All Categories